A detailed history of Gables Capital Management Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Gables Capital Management Inc. holds 8,559 shares of BMY stock, worth $464,924. This represents 0.23% of its overall portfolio holdings.

Number of Shares
8,559
Previous 8,684 1.44%
Holding current value
$464,924
Previous $360,000 22.78%
% of portfolio
0.23%
Previous 0.19%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$39.66 - $51.75 $4,957 - $6,468
-125 Reduced 1.44%
8,559 $442,000
Q1 2024

May 03, 2024

BUY
$47.98 - $54.4 $35,985 - $40,800
750 Added 9.45%
8,684 $470,000
Q4 2023

Feb 07, 2024

BUY
$48.48 - $57.85 $33,936 - $40,495
700 Added 9.68%
7,934 $407,000
Q2 2023

Aug 02, 2023

BUY
$63.71 - $70.74 $23,891 - $26,527
375 Added 5.47%
7,234 $462,000
Q4 2022

Feb 03, 2023

SELL
$68.48 - $81.09 $6,848 - $8,109
-100 Reduced 1.44%
6,859 $493,000
Q2 2021

Aug 03, 2021

SELL
$61.91 - $67.42 $252,283 - $274,736
-4,075 Reduced 36.93%
6,959 $465,000
Q2 2020

Jul 30, 2020

BUY
$54.82 - $64.09 $3,782 - $4,422
69 Added 0.63%
11,034 $649,000
Q1 2020

May 07, 2020

BUY
$46.4 - $67.43 $6,078 - $8,833
131 Added 1.21%
10,965 $617,000
Q4 2019

Feb 10, 2020

BUY
$49.21 - $64.19 $167,314 - $218,246
3,400 Added 45.74%
10,834 $690,000
Q2 2019

Jul 31, 2019

SELL
$44.62 - $49.34 $4,462 - $4,934
-100 Reduced 1.33%
7,434 $340,000
Q1 2019

Apr 30, 2019

SELL
$45.12 - $53.8 $54,144 - $64,560
-1,200 Reduced 13.74%
7,534 $359,000
Q4 2018

Feb 08, 2019

SELL
$48.76 - $63.23 $92,644 - $120,137
-1,900 Reduced 17.87%
8,734 $454,000
Q2 2018

Aug 03, 2018

BUY
$50.53 - $62.98 $40,424 - $50,384
800 Added 8.14%
10,634 $577,000
Q1 2018

May 17, 2018

BUY
$59.92 - $68.98 $589,253 - $678,349
9,834 New
9,834 $622,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $115B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Gables Capital Management Inc. Portfolio

Follow Gables Capital Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gables Capital Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Gables Capital Management Inc. with notifications on news.